A postgraduate research opportunity at the University of Otago.
- Close date
- Sunday, 31 January 2021
- Academic background
- Sciences, Health Sciences
- Host campus
- Honours, Master’s
- Pathology (Dunedin)
- Dr Marina Kazantseva, Dr Tania Slatter
Silencing of tumour suppressor genes by a process called DNA methylation is thought to be an early and driving event in the tumourigenesis and is a hallmark of cancer, but how this epigenetic switch is triggered in cancer cells remains largely unknown. We have evidence that Δ133p53 - truncated oncogenic isoform of the p53 tumour suppressor plays central role in this process.
Preliminary data obtained in lung cancer cell lines engineered to expresses Δ133p53 isoforms showed Δ133p53 may contribute to inactivation of genes that protect us from cancer through DNA modification mechanisms. Here we propose to explore whether we can reactivate tumour suppressor genes silenced in Δ133p53-expressing lung cancer cells using cutting-edge chimeric deactivated CRISPR-dCas9-based technology. This will enable to confirm the functionality of epigenetic modifications induced by the isoform. As epigenetic changes are reversible, this may uncover attractive targets for cancer treatment.
Tel +64 3 479 7169